Vida Pharmacal

Vida Pharmacal is a privately held Texas pharmaceutical and diagnostics company focused on emerging and neglected diseases in both veterinary and human health. The company is best known for developing programs for Chagas disease caused by Trypanosoma cruzi, including what it describes as the first treatment for canine Chagas disease and a companion diagnostic effort. Its lead therapeutic program, V1001, is an oral small-molecule combination based on itraconazole + amiodarone, and its pipeline also includes point-of-care and serologic diagnostic assays for Chagas disease and Leishmania. Vida organizes its business across animal health and human health divisions and also offers bioanalytic PCR laboratory services. The company appears to remain at an early development stage and is primarily focused on neglected tropical diseases with initial emphasis on canine and feline applications.